Cases in Prevention: Where the Latest Research on Diabetic Retinopathy Meets the Real World

Released On
January 30, 2020

Expires On
January 31, 2021

Media Type

Completion Time
90 minutes



Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by Wills Eye Hospital and MedEdicus LLC


This activity is supported through an unrestricted educational grant from Regeneron Pharmaceuticals, Inc.

Credit Available

  • Physicians — maximum of 1.5 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Program Overview

Diabetic retinopathy can now be treated earlier to prevent vision-threatening complications. This activity reviews the latest data and strategies.

Learning Objectives

Upon completion of this activity, participants should be able to:

  1. Evaluate the evidence supporting treatment for preventing vision-threatening outcomes in diabetic retinopathy
  2. Design treatment plans for diabetic retinopathy that consider individual patient factors
  3. Describe clinical trial data supporting treatment of moderate-to-severe nonproliferative diabetic retinopathy to prevent proliferative diabetic retinopathy and diabetic macular edema
  4. Integrate imaging and communication tools into practice to help patients prevent vision loss due to diabetic retinopathy


Julia A. Haller, MD

Wills Eye Hospital
Chair and Professor
Department of Ophthalmology
Sidney Kimmel Medical College
Thomas Jefferson University
Philadelphia, Pennsylvania

Sunir J. Garg, MD

Professor of Ophthalmology
Sidney Kimmel Medical College
Thomas Jefferson University
Attending Physician
Retina Service
Wills Eye Hospital
Philadelphia, Pennsylvania

SriniVas R. Sadda, MD

President and Chief Scientific Officer
Stephen J. Ryan-Arnold and Mabel Beckman Foundation Endowed Presidential Chair
Doheny Eye Institute
Professor of Ophthalmology
University of California, Los Angeles
Los Angeles, California

Charles C. Wykoff, MD, PhD

Director of Research
Retina Consultants of Houston
Blanton Eye Institute
Houston Methodist Hospital
Clinical Associate Professor of Ophthalmology
Weill Cornell Medical College
Houston, Texas

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Wills Eye Hospital and MedEdicus LLC. Wills Eye Hospital is accredited by the ACCME to provide continuing medical education for physicians.


As a provider accredited by the ACCME, Wills Eye Hospital must ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. All faculty participating in this CME activity were asked to disclose the following:

  1. Names of proprietary entities producing health care goods or services—with the exemption of nonprofit or government organizations and non–health-related companies—with which they or their spouse/partner have, or have had, a relevant financial relationship within the past 12 months. For this purpose, we consider the relevant financial relationships of a spouse/partner of which they are aware to be their financial relationships.
  2. Describe what they or their spouse/partner received (eg, salary, honorarium).
  3. Describe their role.
  4. No relevant financial relationships.


Disclosures of Conflicts of Interest

CME Reviewer:
  • Ralph C. Eagle Jr, MD, has no relevant financial relationships with any commercial interests.
  • Dr Sunir J. Garg is a consultant for Bausch & Lomb Incorporated; Deciphera Pharmaceuticals, Inc; Johnson & Johnson Vision Care, Inc; and TopiVert Ltd; and a contracted researcher for Aerpio Therapeutics; Allergan; Apellis Pharmaceuticals; and Wills Eye Hospital.
  • Dr Julia A. Haller is a consultant for KalVista Pharmaceuticals; Novartis Pharmaceuticals Corporation; and Spark Therapeutics, Inc; board member of Celgene Corporation; and a data safety monitoring board member of Aura Biosciences, Inc; and Janssen Global Services, LLC.
  • Dr SriniVas R. Sadda is a consultant for Allergan; Amgen; Bayer Corporation; CenterVue SpA; Eyenuk, Inc (past); F. Hoffman-La Roche Ltd; Genentech, Inc; Heidelberg Engineering GmbH; Novartis Pharmaceuticals Corporation; Optos; and 4DMT; and received other funding (research instruments) from Carl Zeiss Meditec, Inc; CenterVue SpA; Heidelberg Engineering GmbH; NIDEK Inc; Optos; and Topcon Medical Systems, Inc.
  • Dr Charles C. Wykoff is a consultant for Adverum; Aerpio Therapeutics; Alimera Sciences; Allegro Ophthalmics, LLC; Allergan; Apellis Pharmaceuticals; Bayer Corporation; Clearside Biomedical, Inc; D.O.R.C.; EyePoint Pharmaceuticals; F. Hoffmann-La Roche Ltd; Genentech, Inc; IVERIC bio; Kodiak Sciences Inc; Novartis Pharmaceuticals Corporation; ONL Therapeutics; Polyphotonix; Recens Medical Co, Ltd; Regeneron Pharmaceuticals, Inc; Regenxbio Inc; Santen Inc; Shanghai Fosun Pharmaceutical (Group) Co, Ltd; and Takeda Pharmaceuticals USA, Inc; and is a contracted researcher for Adverum; Aerpio Therapeutics; Allergan; Apellis Pharmaceuticals; Chengdu Kanghong Pharmaceuticals Group Co, Ltd; Clearside Biomedical, Inc; F. Hoffmann-La Roche Ltd; Genentech, Inc; IVERIC bio; Kodiak Sciences Inc; Neurotech Pharmaceuticals; Novartis Pharmaceuticals Corporation; Opthea; Recens Medical Co, Ltd; Regeneron Pharmaceuticals, Inc; Regenxbio Inc; Samsung; and Santen Inc.
Planning Committee: The faculty have relevant commercial relationships as described above.
  • Erika Langsfeld, PhD; Cynthia Tornallyay, RD, MBA, CHCP; Michelle Ong; and Wills Eye Hospital Staff and Advisory Board have no real or apparent financial relationships with any commercial interests.

Method of Participation

This course takes approximately 1.5 hours. Please read the monograph, consulting any additional references if needed. Once the materials have been reviewed, complete the post test and evaluation found at the end of the activity, after which you will be able to generate your CME certificate.

Special Services

If you need special accommodations because of a disability or for an alternative form of course materials, please contact us at or (215) 440-3168. Wills Eye Hospital fully complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof.


The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Wills Eye Hospital, MedEdicus LLC, or Regeneron Pharmaceuticals, Inc.

Contact Information

For questions about the CME activity content, please contact Wills Eye Hospital at or (215) 440-3168.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

Privacy Policy

All information provided by course participants is confidential and will not be shared with any other parties for any reason without permission.